BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 18644721)

  • 1. Achieving multi-isoform PI3K inhibition in a series of substituted 3,4-dihydro-2H-benzo[1,4]oxazines.
    Perry B; Alexander R; Bennett G; Buckley G; Ceska T; Crabbe T; Dale V; Gowers L; Horsley H; James L; Jenkins K; Crépy K; Kulisa C; Lightfoot H; Lock C; Mack S; Morgan T; Nicolas AL; Pitt W; Sabin V; Wright S
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4700-4. PubMed ID: 18644721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of a series of multi-isoform PI3 kinase inhibitors.
    Perry B; Beevers R; Bennett G; Buckley G; Crabbe T; Gowers L; James L; Jenkins K; Lock C; Sabin V; Wright S
    Bioorg Med Chem Lett; 2008 Oct; 18(19):5299-302. PubMed ID: 18774713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3,4-Dihydro-2H-benzo[1,4]oxazine derivatives as 5-HT6 receptor antagonists.
    Zhao SH; Berger J; Clark RD; Sethofer SG; Krauss NE; Brothers JM; Martin RS; Misner DL; Schwab D; Alexandrova L
    Bioorg Med Chem Lett; 2007 Jun; 17(12):3504-7. PubMed ID: 17485206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of piperidine carboxamide TRPV1 antagonists.
    Cheung WS; Calvo RR; Tounge BA; Zhang SP; Stone DR; Brandt MR; Hutchinson T; Flores CM; Player MR
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4569-72. PubMed ID: 18662879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitors.
    Anderson M; Andrews DM; Barker AJ; Brassington CA; Breed J; Byth KF; Culshaw JD; Finlay MR; Fisher E; McMiken HH; Green CP; Heaton DW; Nash IA; Newcombe NJ; Oakes SE; Pauptit RA; Roberts A; Stanway JJ; Thomas AP; Tucker JA; Walker M; Weir HM
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5487-92. PubMed ID: 18815031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and structure-activity relationship of novel 6-aryl-1,4-dihydrobenzo[d][1,3]oxazine-2-thiones as progesterone receptor modulators leading to the potent and selective nonsteroidal progesterone receptor agonist tanaproget.
    Fensome A; Bender R; Chopra R; Cohen J; Collins MA; Hudak V; Malakian K; Lockhead S; Olland A; Svenson K; Terefenko EA; Unwalla RJ; Wilhelm JM; Wolfrom S; Zhu Y; Zhang Z; Zhang P; Winneker RC; Wrobel J
    J Med Chem; 2005 Aug; 48(16):5092-5. PubMed ID: 16078826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and optimization of thieno[2,3-d]pyrimidines as B-Raf inhibitors.
    Packard GK; Papa P; Riggs JR; Erdman P; Tehrani L; Robinson D; Harris R; Shevlin G; Perrin-Ninkovic S; Hilgraf R; McCarrick MA; Tran T; Fleming Y; Bai A; Richardson S; Katz J; Tang Y; Leisten J; Moghaddam M; Cathers B; Zhu D; Sakata S
    Bioorg Med Chem Lett; 2012 Jan; 22(1):747-52. PubMed ID: 22137342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification, synthesis and SAR of amino substituted pyrido[3,2b]pyrazinones as potent and selective PDE5 inhibitors.
    Owen DR; Walker JK; Jon Jacobsen E; Freskos JN; Hughes RO; Brown DL; Bell AS; Brown DG; Phillips C; Mischke BV; Molyneaux JM; Fobian YM; Heasley SE; Moon JB; Stallings WC; Joseph Rogier D; Fox DN; Palmer MJ; Ringer T; Rodriquez-Lens M; Cubbage JW; Blevis-Bal RM; Benson AG; Acker BA; Maddux TM; Tollefson MB; Bond BR; Macinnes A; Yu Y
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4088-91. PubMed ID: 19540112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and discovery of 2,3-dihydro-3,8-diphenylbenzo[1,4]oxazines as a novel class of potent cholesteryl ester transfer protein inhibitors.
    Wang A; Prouty CP; Pelton PD; Yong M; Demarest KT; Murray WV; Kuo GH
    Bioorg Med Chem Lett; 2010 Feb; 20(4):1432-5. PubMed ID: 20089400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of 3,4-dihydro-2H-benzo[1,4]oxazine derivatives as dual thromboxane A2 receptor antagonists and prostacyclin receptor agonists.
    Ohno M; Tanaka Y; Miyamoto M; Takeda T; Hoshi K; Yamada N; Ohtake A
    Bioorg Med Chem; 2006 Mar; 14(6):2005-21. PubMed ID: 16297632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of LFA-1 antagonists based on a 2,3-dihydro-1H-pyrrolizin-5(7aH)-one scaffold.
    Dodd DS; Sheriff S; Chang CJ; Stetsko DK; Phillips LM; Zhang Y; Launay M; Potin D; Vaccaro W; Poss MA; McKinnon M; Barrish JC; Suchard SJ; Murali Dhar TG
    Bioorg Med Chem Lett; 2007 Apr; 17(7):1908-11. PubMed ID: 17291752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis of 2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as platelet aggregation inhibitors.
    Tian X; Wang LY; Xia S; Li ZB; Liu XH; Yuan Y; Fang L; Zuo H
    Bioorg Med Chem Lett; 2012 Jan; 22(1):204-6. PubMed ID: 22137848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, DNA-PK inhibition, anti-platelet activity studies of 2-(N-substituted-3-aminopyridine)-substituted-1,3-benzoxazines and DNA-PK and PI3K inhibition, homology modelling studies of 2-morpholino-(7,8-di and 8-substituted)-1,3-benzoxazines.
    Ihmaid SK; Al-Rawi JM; Bradley CJ; Angove MJ; Robertson MN
    Eur J Med Chem; 2012 Nov; 57():85-101. PubMed ID: 23059543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of 4'-substituted bicyclic pyridones as non-steroidal inhibitors of steroid 5alpha-reductase.
    McCarthy AR; Hartmann RW; Abell AD
    Bioorg Med Chem Lett; 2007 Jul; 17(13):3603-7. PubMed ID: 17490876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indole RSK inhibitors. Part 1: discovery and initial SAR.
    Boyer SJ; Burke J; Guo X; Kirrane TM; Snow RJ; Zhang Y; Sarko C; Soleymanzadeh L; Swinamer A; Westbrook J; Dicapua F; Padyana A; Cogan D; Gao A; Xiong Z; Madwed JB; Kashem M; Kugler S; O'Neill MM
    Bioorg Med Chem Lett; 2012 Jan; 22(1):733-7. PubMed ID: 22100312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies toward the discovery of the next generation of antidepressants. Part 5: 3,4-Dihydro-2H-benzo[1,4]oxazine derivatives with dual 5-HT1A receptor and serotonin transporter affinity.
    Zhou D; Harrison BL; Shah U; Andree TH; Hornby GA; Scerni R; Schechter LE; Smith DL; Sullivan KM; Mewshaw RE
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1338-41. PubMed ID: 16332439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 4-Phenyl-7-azaindoles as potent and selective IKK2 inhibitors.
    Liddle J; Bamborough P; Barker MD; Campos S; Cousins RP; Cutler GJ; Hobbs H; Holmes DS; Ioannou C; Mellor GW; Morse MA; Payne JJ; Pritchard JM; Smith KJ; Tape DT; Whitworth C; Williamson RA
    Bioorg Med Chem Lett; 2009 May; 19(9):2504-8. PubMed ID: 19349179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and biological evaluation of novel series of 2H-benzo[b][1,4]oxazin-3(4H)-one and 2H-benzo[b][1,4]oxazine scaffold derivatives as PI3Kα inhibitors.
    Dong FD; Liu DD; Deng CL; Qin XC; Chen K; Wang J; Song HR; Ding HW
    Bioorg Med Chem; 2018 Aug; 26(14):3982-3991. PubMed ID: 29937355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2-(6-Phenyl-1H-indazol-3-yl)-1H-benzo[d]imidazoles: design and synthesis of a potent and isoform selective PKC-zeta inhibitor.
    Trujillo JI; Kiefer JR; Huang W; Thorarensen A; Xing L; Caspers NL; Day JE; Mathis KJ; Kretzmer KK; Reitz BA; Weinberg RA; Stegeman RA; Wrightstone A; Christine L; Compton R; Li X
    Bioorg Med Chem Lett; 2009 Feb; 19(3):908-11. PubMed ID: 19097791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and PKCtheta inhibitory activity of a series of 4-indolylamino-5-phenyl-3-pyridinecarbonitriles.
    Dushin RG; Nittoli T; Ingalls C; Boschelli DH; Cole DC; Wissner A; Lee J; Yang X; Morgan P; Brennan A; Chaudhary D
    Bioorg Med Chem Lett; 2009 May; 19(9):2461-3. PubMed ID: 19345579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.